Loading data for BMY — first visit, this takes a few seconds.

Alert

Bristol-Myers Squibb (BMY)

NYSE: BMY · Real-Time Price · USD

66.58

-0.37 (-0.55%)

At close: Aug 28, 2026, 8:00 PM

66.60

+0.03%

After-hours: 7:55 PM

The price, the headline numbers and the latest news, in one place.

-0.55% (1D)

No data available

Bid	66.45
Market Cap	136B
Revenue (ttm)	49.19B
Net Income (ttm)	9.28B
	0.23
	4.54
	14.67
	10.15
P/B (ttm)	6.09
P/S (ttm)	2.77
Earnings Date	Oct 29, 2026

Ask	67.02
Volume	5,542,352
Avg. Volume (20D)	11,965,812
Open	66.77
Previous Close	66.95
Day's Range	66.19 - 66.84
52-Week Range	42.52 - 68.64
Analyst	n/a
Price Target	n/a
Dividends	$2.52 (3.76%)
Ex-Dividend Date	Jul 2, 2026

About BMY

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy f...

[Read more]

Industry Drug Manufacturers - General

Sector Healthcare

IPO Date Jun 1, 1972

Employees 32,500

Stock Exchange NYSE

Ticker Symbol BMY

Website https://www.bms.com

Full Company Profile

Financial Performance

In 2025, Bristol-Myers Squibb's revenue was 48.2B, a decrease of -0.22% compared to the previous year's 48.3B. Earnings were 7.05B, a decrease of -178.83%.

Financial Statements

Earnings Surprise

Bristol-Myers Squibb has released their quarterly earnings on Jul 30, 2026:

Revenue of $12.97B misses estimates by $0, with 5.74% YoY growth.
EPS of 2.04 exceeds estimates by 0.44, with 39.73% YoY growth.

Next Earnings Release

Bristol-Myers Squibb is scheduled to release its earnings on Oct 29, 2026, before market opens.
Analysts project revenue of ... Upgrade

News

12 hours ago · Investor's Business Daily

Cytokinetics Boasts A First-Ever In Heart Disease — And Shares Drop

Cytokinetics scored the first-ever win for a Phase 3 study in non-obstructive hypertrophic cardiomyopathy on Friday.

12 hours ago · Insider Monkey

Can Atrium Therapeutics (RNA)’s $15 Million Milestone From Bristol-Myers Squibb (BMY) Validate its RNA Platform?

On August 13, two pharmaceutical companies tied to the same cardiovascular research deal delivered major updates. Atrium Therapeutics, Inc. (NASDAQ:RNA) earned a $15 million milestone payment from Bri...

13 hours ago · Trefis

Can Merck Stock Outrun Its Pipeline?

Revenue grew at its usual pace over the past year while the stock outran its biggest peers, and the gap sits in a run of clinical readouts that landed early.

20 hours ago · StockStory

1 S&P 500 Stock with Promising Prospects and 2 Facing Challenges

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, h...

1 day ago · Insider Monkey

Bristol-Myers Squibb (BMY)’s Cellares Exit Raises Questions Over Breyanzi Growth

Bristol-Myers Squibb Company (NYSE:BMY) has ended its partnership with cell-therapy manufacturer Cellares after determining that Cellares’ Cell Shuttle platform could not meet the requirements needed ...

Page 1 of 2

Bristol-Myers Squibb (BMY)